Navigation Links
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

se events included fatigue, hand/foot syndrome and skin rash.

The lead investigator for this study is Joan Schiller, MD, professor and chief of the hematology/oncology division at the University of Texas Southwestern and Andrea L. Simmons distinguished chair in cancer research, Dallas, TX. (abstract #8014).

Thyroid Cancer

A Phase 2 Study of Sorafenib in Metastatic Thyroid Carcinoma

Findings from this single-arm Phase 2 study showed that treatment with Nexavar resulted in meaningful anti-tumor activity in the majority of patients with encouraging overall clinical benefit (disease stabilization and partial responses) in patients with advanced thyroid cancer. In the study, Nexavar was well-tolerated; the most common treatment-related adverse events included fatigue, rash, diarrhea, palmer-plantar erythema, musculoskeletal pain and weight loss. Patients enrolled in this study had been diagnosed with metastatic, iodine-refractory, unresectable or locally-advanced thyroid cancer.

The lead investigator for this study is Marcia S. Brose, MD, PhD, assistant professor, director of cancer genetics laboratory, University of Pennsylvania Health System, Philadelphia, PA. (abstract #6026).

Gastrointestinal Stromal Tumors

Activity of Sorafenib in Patients with Imatinib and Sunitinib-Resistant Gastrointestinal Stromal Tumors (GIST): A Phase 2 Trial of the University of Chicago Phase 2 Consortium

Findings from this single-arm Phase 2 study suggest that Nexavar is active and well tolerated in patients with Gleevec or Gleevec and Sutent resistant GIST. The most common treatment-emergent adverse events included hand-foot syndrome, hypertension, rash and diarrhea.

The lead investigator for this study is Lauren Wiebe, MD, fellow, University of Chicago, Chicago, IL. (abstract #10502).

Gastric/GEJ

A Phase 2 Study: Combination of Sorafenib with Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Unres
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
2. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
3. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
10. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015  Celsion Corporation (NASDAQ: ... will host a conference call to discuss year-end ... its development programs for ThermoDox®, its proprietary heat-activated ... technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy and ... March 12, 2015. To participate in the call, ...
(Date:3/5/2015)... 2015 Research and Markets ( ... "Global Pharma US & EU Outlook 2015: ... Role In Shaping Up Business for Large Cap ... Strategy Diversification Divested: Productivity measurements, Divestment ... Will accelerate Next wave of targeted acquisition ...
(Date:3/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5sqnn3/global_rising ) has ... Outlook 2015" report to their offering. ... after with fresh vigor as new targets , approaches ... to bring a paradigm change in the way diseases ... cell therapy/Regenerative Medicine space. The number of ...
Breaking Medicine Technology:Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 2Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 3Global Pharma Rising Stars Outlook 2015 2
(Date:3/5/2015)... MS (PRWEB) March 05, 2015 At ... Basics and Beyond,” leaders in addiction treatment met today ... updates in best clinical practices. Among the numerous respected ... , who will address the role that pain medications ... and new evidence-based treatment options. , "It is hard ...
(Date:3/5/2015)... Califia Farms , the leading ... Products Expo West that its popular ready-to-drink Vanilla and ... and dairy free. Califia Farms Vegan Protein Almondmilk drinks ... packed with six grams of an innovative nutrient-dense, pea ... vitamins and magnesium. , Protein is an essential part ...
(Date:3/5/2015)... University of Western States (UWS), ... has launched a new center of excellence to ... Northwest Center for Lifestyle and Functional Medicine aim ... and conduct research in the areas of lifestyle ... The center will target efforts on the UWS ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Supply & ... annual listing of “Pros to Know” in the supply ... two members of MEBC’s leadership team were included on ... nominated and received this award due to their hard ... innovative methods for meeting and resolving client needs and ...
(Date:3/5/2015)... New York, NY (PRWEB) March 05, 2015 ... NY orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named ... in the New York Metro area. Dr. Glashow has ... in its authoritative guide to the top specialty care ... 2015. , The prestigious Castle Connolly program, which carefully ...
Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2
... among the most economically costly sports injuries, are the ... a study conducted at the Center for Injury Research ... Childrens Hospital and published in the June issue of ... utilized data from the High School RIOTM online ...
... May 21 The American Lung,Association has launched ... the,public,s help in exposing the most egregious examples ... nationwide. These photos,will highlight the urgent need for ... Control Act (S.625/HR 1108)., The American Lung ...
... into the causes of cervical cancer appears to lend weight ... could help prevent the disease. , According to a study ... Hill, persistent infection with human papillomavirus (HPV) could be a ... second most common cancer in women worldwide. , HPV ...
... Adverse Events in TORCH Showed Frequency Highest in ... ... N.C., May 21 /PRNewswire-FirstCall/,-- The use of Advair Diskus(R) 500/50 (fluticasone ... adverse events compared to other treatment arms in a,post-hoc analysis of ...
... CEO of Jurlique, an,independent natural beauty company, was ... in New York on Friday, May 16th. This ... in Paris, had been held in,America., The ... manufacturers, ingredient suppliers, packaging companies,retailers, industry organizations, investors ...
... in Three of the Last Four ... ... PER ) and Harvard Pilgrim Health Care were named by the,Outsourcing ... by the Everest Group and Forbes,magazine, these awards honor the most outstanding ...
Cached Medicine News:Health News:First of its kind study compares high school knee injuries by sport and gender 2Health News:American Lung Association Launches Online Photo Campaign to Expose Big Tobacco in Communities Nationwide 2Health News:UNC study firms up promise of potential new cervical cancer screening tool 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3Health News:CEO of Jurlique Issues Industry Call to Action at Natural Beauty Summit 2Health News:CEO of Jurlique Issues Industry Call to Action at Natural Beauty Summit 3Health News:Harvard Pilgrim Health Care and Perot Systems Named as 'Best Partnership' by Outsourcing Center 2Health News:Harvard Pilgrim Health Care and Perot Systems Named as 'Best Partnership' by Outsourcing Center 3Health News:Harvard Pilgrim Health Care and Perot Systems Named as 'Best Partnership' by Outsourcing Center 4Health News:Harvard Pilgrim Health Care and Perot Systems Named as 'Best Partnership' by Outsourcing Center 5
... temporary internal drainage from the ureteropelvic junction ... engineered for ease of placement and patient ... designed for repositioning and ease of removal. ... polymer that when activated, attracts and holds ...
... The Panbio West Nile Virus IgM ... detection of IgM antibodies to West Nile ... the clinical laboratory diagnosis of West Nile ... consistent with encephalitis / meningitis. Positive results ...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: